Insider Selling: Humana (NYSE:HUM) Insider Sells $2,384,005.75 in Stock

Humana Inc. (NYSE:HUM) insider Joseph Ventura sold 5,495 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $433.85, for a total value of $2,384,005.75. Following the transaction, the insider directly owned 21,910 shares of the company’s stock, valued at $9,505,653.50. The trade was a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Humana Stock Down 0.9%

Shares of HUM traded down $3.91 during midday trading on Thursday, hitting $442.40. The company had a trading volume of 276,570 shares, compared to its average volume of 1,645,875. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $456.50. The company’s 50-day simple moving average is $406.79 and its 200-day simple moving average is $314.80. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.74 and a current ratio of 1.65. The firm has a market capitalization of $53.13 billion, a P/E ratio of 42.93, a P/E/G ratio of 2.30 and a beta of 0.65.

Humana (NYSE:HUM) last announced its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.30. The business had revenue of $41.16 billion for the quarter, compared to analyst estimates of $40.87 billion. Humana had a net margin of 0.81% and a return on equity of 8.50%. The company’s revenue was up 26.1% on a year-over-year basis. During the same period last year, the business earned $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, sell-side analysts expect that Humana Inc. will post 9.56 EPS for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Stockholders of record on Thursday, December 24th will be paid a dividend of $0.8850 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, December 24th. Humana’s payout ratio is 34.44%.

Analyst Ratings Changes

HUM has been the topic of several research reports. JPMorgan Chase & Co. increased their price target on shares of Humana from $393.00 to $484.00 and gave the company a “neutral” rating in a research report on Tuesday. Raymond James Financial restated an “outperform” rating on shares of Humana in a research report on Friday, November 6th. Zacks Research upgraded Humana from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Cantor Fitzgerald increased their price target on Humana from $460.00 to $495.00 and gave the stock an “overweight” rating in a research note on Monday. Finally, Citigroup began coverage on Humana in a report on Friday, October 9th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $476.52.

Latest Humana News

These are some of the HUM news items that stood out recently:

• Positive Sentiment: Zacks Research upgraded Humana to Strong Buy, citing improving earnings prospects. A separate report also noted a fair-value increase following the company’s star-rating update and third-quarter results. Zacks Strong Buy upgrade Fair-value assessment
• Positive Sentiment: Humana’s new oncology-care model with Evolent and American Oncology Network aims to streamline cancer treatment by reducing prior-authorization hurdles. The initiative may support its broader value-based-care strategy, though its financial impact is not yet clear. Oncology model analysis
• Negative Sentiment: TD Cowen raised its target to $430 from $370 but kept a Hold rating; that target is below the $446.33 reference price, offering a more cautious counterpoint to recent bullish calls. Analyst and company updates

Institutional Trading of Humana

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Humana in the 2nd quarter valued at about $4,138,160,000. State Street Corp increased its position in Humana by 1.6% during the 3rd quarter. State Street Corp now owns 5,543,942 shares of the insurance provider’s stock worth $2,115,402,000 after purchasing an additional 86,870 shares in the last quarter. Pzena Investment Management LLC acquired a new stake in Humana during the 2nd quarter worth approximately $1,749,014,000. Assenagon Asset Management S.A. raised its holdings in Humana by 20,126.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,255,479 shares of the insurance provider’s stock valued at $479,053,000 after buying an additional 1,249,272 shares during the period. Finally, Legal & General Group Plc purchased a new position in Humana in the second quarter valued at approximately $329,760,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Humana

Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.